HOME >> BIOLOGY >> NEWS
Exisulind (Aptosyn™) and other SAANDs compounds halt prostate cancer cell growth by two mechanisms

HORSHAM, PA (April 3, 2000) -- Exisulind (Aptosyn™) and other selective apoptotic antineoplastic drugs (SAANDs) inhibit the growth of prostate cancer cells in two ways, said researchers from Columbia University and their collaborators at Cell Pathways, Inc. (Nasdaq: CLPA). First, they directly kill cancerous prostate cells by inducing apoptosis. Secondly, they decrease expression of the androgen receptor in the cancerous prostate cells, making them less responsive to the growth-promoting effects of androgens in their environment. The Columbia University scientists and their Cell Pathways' collaborators presented their preclinical findings on Sunday April 2, 2000 at the annual meeting of the American Association for Cancer Research (AACR) in San Francisco.

The researchers also demonstrated in a prostate cancer cell line that exisulind (Aptosyn™) and two other SAANDs, CP461 and CP248, inhibited the cellular expression and secretion of prostate specific antigen (PSA) at the same concentrations that induced apoptosis in the cells.

Dr. Bernard Weinstein, the senior investigator of these studies and director of the Columbia University Comprehensive Cancer Center, emphasized that "because of their dual mechanism of action, these agents are also effective in prostate cancer cells that have become independent of androgens."

"These findings also support the usefulness of PSA assays for measuring the efficacy of SAANDs in clinical trials for prostate cancer therapy or chemoprevention, as they demonstrate that a reduction in PSA levels accurately reflects cell death and not merely a reduction in PSA production when these drugs are used," added Rifat Pamukcu, M.D., chief scientific officer and senior vice president of research at Cell Pathways, Inc.

"This laboratory research complements the findings of our clinical trial of exisulind (Aptosyn™) as a treatment for post-prostatectomy men at risk of prostate cancer recurre
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
2-Apr-2000


Page: 1 2 3

Related biology news :

1. New molecular link key to cellular proteins involved in cancer progression, other diseases
2. New hydrothermal vents discovered as South Pacific Odyssey research begins
3. Posters highlight water, energy and other natural resource research
4. Joslin Diabetes Center honors brothers living 70-plus years with type 1 diabetes
5. K-State, other universities to study how climate affects plant evolution
6. The search for a kinder, gentler chemotherapy
7. Green tea research leads to gum and other products
8. New survey reveals insights into unique relationship between mothers and pediatricians
9. Manatee population rising in some regions, likely stalled or declining in others
10. Study shows impact of emotionally healthy fathers when mothers poor mental health affects children
11. Another key for the p53 door

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... , ... May 23, 2017 , ... ... as Vice President of Clinical Operations. She brings years of expertise in ... Therapeutics. From her professional foundation as a licensed occupational therapist, through a variety ...
(Date:5/22/2017)... ... 22, 2017 , ... Stratevi, a boutique firm that partners with healthcare companies ... opened an office in downtown Boston at 745 Atlantic Ave. , “We are ... generate evidence on the value they provide, not just to patients, but also payers. ...
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose is a genetically driven, ... process by finding the right antidepressant faster. CNSDose speeds recovery and reduces ... a personalized approach to treatment. , A peer-reviewed and published, 12-week ...
(Date:5/18/2017)... ... May 18, 2017 , ... Lajollacooks4u has added another ... a two-hour team-building package designed for groups of 10-30 people. Guests can ... include items, such as Blackened Shrimp with Edamame Salad, Pizza Rolls with Pepperoni ...
Breaking Biology Technology:
Cached News: